120 related articles for article (PubMed ID: 38677763)
21. Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.
Liu H; Qian F
Theranostics; 2022; 12(3):1321-1332. PubMed ID: 35154489
[TBL] [Abstract][Full Text] [Related]
22. Silmitasertib-induced macropinocytosis promoting DDP intracellular uptake to enhance cell apoptosis in oral squamous cell carcinoma.
Song S; Xia X; Qi J; Hu X; Chen Q; Liu J; Ji N; Zhao H
Drug Deliv; 2021 Dec; 28(1):2480-2494. PubMed ID: 34766543
[TBL] [Abstract][Full Text] [Related]
23. Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2.
Kim D; Min D; Kim J; Kim MJ; Seo Y; Jung BH; Kwon SH; Ro H; Lee S; Sa JK; Lee JY
J Exp Clin Cancer Res; 2023 Dec; 42(1):338. PubMed ID: 38093368
[TBL] [Abstract][Full Text] [Related]
24. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
[TBL] [Abstract][Full Text] [Related]
25. L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating
Kim H; Hwang H; Lee H; Hong HJ
Mol Cells; 2017 May; 40(5):363-370. PubMed ID: 28535665
[TBL] [Abstract][Full Text] [Related]
26. Gold Nanoparticles Inhibit Macropinocytosis by Decreasing KRAS Activation.
Elechalawar CK; Rao G; Gulla SK; Patel MM; Frickenstein A; Means N; Roy RV; Tsiokas L; Asfa S; Panja P; Rao C; Wilhelm S; Bhattacharya R; Mukherjee P
ACS Nano; 2023 May; 17(10):9326-9337. PubMed ID: 37129853
[TBL] [Abstract][Full Text] [Related]
27. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging.
Sutton MN; Gammon ST; Muzzioli R; Pisaneschi F; Radaram B; Yang P; Piwnica-Worms D
Mol Imaging Biol; 2022 Jun; 24(3):498-509. PubMed ID: 34905147
[TBL] [Abstract][Full Text] [Related]
28. Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
So KS; Kim CH; Rho JK; Kim SY; Choi YJ; Song JS; Kim WS; Choi CM; Chun YJ; Lee JC
PLoS One; 2014; 9(12):e114000. PubMed ID: 25486409
[TBL] [Abstract][Full Text] [Related]
29. Hyperstimulation of macropinocytosis leads to lysosomal dysfunction during exposure to methamphetamine in SH-SY5Y cells.
Nara A; Aki T; Funakoshi T; Unuma K; Uemura K
Brain Res; 2012 Jul; 1466():1-14. PubMed ID: 22613348
[TBL] [Abstract][Full Text] [Related]
30. MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.
Bian Y; Han J; Kannabiran V; Mohan S; Cheng H; Friedman J; Zhang L; VanWaes C; Chen Z
Int J Biol Sci; 2015; 11(4):411-22. PubMed ID: 25798061
[TBL] [Abstract][Full Text] [Related]
31. TGF-β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: A study on human primary cell cultures.
Lustri AM; Di Matteo S; Fraveto A; Costantini D; Cantafora A; Napoletano C; Bragazzi MC; Giuliante F; De Rose AM; Berloco PB; Grazi GL; Carpino G; Alvaro D
PLoS One; 2017; 12(9):e0183932. PubMed ID: 28873435
[TBL] [Abstract][Full Text] [Related]
32. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
[TBL] [Abstract][Full Text] [Related]
33. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism.
Lertsuwan J; Lertsuwan K; Sawasdichai A; Tasnawijitwong N; Lee KY; Kitchen P; Afford S; Gaston K; Jayaraman PS; Satayavivad J
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30142881
[TBL] [Abstract][Full Text] [Related]
34. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.
So KS; Rho JK; Choi YJ; Kim SY; Choi CM; Chun YJ; Lee JC
Anticancer Res; 2015 Mar; 35(3):1537-42. PubMed ID: 25750308
[TBL] [Abstract][Full Text] [Related]
35. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
36. Alterations in chemokine receptor CCR5 activity influence tumor cell biology in human cholangiocarcinoma cell lines.
Yang J; Sontag D; Gong Y; Minuk GY
Ann Hepatol; 2021; 21():100265. PubMed ID: 33045415
[TBL] [Abstract][Full Text] [Related]
37. Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
Kim HM; Jeong I; Kim HJ; Kang SK; Kwon WS; Kim TS; Park KH; Jung M; Soong J; Lin SC; Chung HC; Rha SY
Anticancer Res; 2018 Nov; 38(11):6171-6180. PubMed ID: 30396934
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of casein kinase 2 prevents growth of human osteosarcoma.
Takahashi K; Setoguchi T; Tsuru A; Saitoh Y; Nagano S; Ishidou Y; Maeda S; Furukawa T; Komiya S
Oncol Rep; 2017 Feb; 37(2):1141-1147. PubMed ID: 27959425
[TBL] [Abstract][Full Text] [Related]
39. Atypical KRAS
Hobbs GA; Baker NM; Miermont AM; Thurman RD; Pierobon M; Tran TH; Anderson AO; Waters AM; Diehl JN; Papke B; Hodge RG; Klomp JE; Goodwin CM; DeLiberty JM; Wang J; Ng RWS; Gautam P; Bryant KL; Esposito D; Campbell SL; Petricoin EF; Simanshu DK; Aguirre AJ; Wolpin BM; Wennerberg K; Rudloff U; Cox AD; Der CJ
Cancer Discov; 2020 Jan; 10(1):104-123. PubMed ID: 31649109
[TBL] [Abstract][Full Text] [Related]
40. Anti-adipogenic and Pro-lipolytic Effects on 3T3-L1 Preadipocytes by CX-4945, an Inhibitor of Casein Kinase 2.
Yadav AK; Jang BC
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]